RICHMOND, BC / ACCESSWIRE / February 24, 2017 / Liberty Biopharma Inc. (LTY.V) ("Liberty Biopharma" or "Company"). A study from the Perelman School of Medicine at the University of Pennsylvania has found that adult stem cells collected from human fat are distinctly more stable than other stem cells, such as fibroblasts from the skin, and have the potential for use in new therapies for the prevention and treatment of aging-related diseases. The discovery was made while the researchers were developing a new model to study chronological aging of these cells. The findings were published this month in the journal Stem Cells.
The researchers found that stem cells collected directly from human fat - called adipose-derived stem cells (ASCs) - can make more proteins than originally thought. This gives ASCs the ability to replicate and maintain their stability, a finding that held true in cells collected from patients 24 - 64 years old.
"The findings of this study are encouraging for the ASC therapies that are being developed by Liberty Biopharma," stated Dr. Richard Cook, MD, MSc, FRCSC, Chief Medical Officer of Liberty Biopharma. "The University of Pennsylvania researchers' findings suggest that ASCs may be particularly useful for anti-aging therapies. The study also demonstrated that ASCs are very robust in patients as old as 64 years of age. If the findings from this study are correct, the Liberty Biopharma System for isolating fresh ASCs may be able to support therapeutic options for older patients, whose need for stem-cell therapies is often greater."
Learn more at the following web pages:
About Liberty Biopharma Inc.
Liberty Biopharma is a clinical stage biopharmaceutical company developing and commercializing regenerative stem cell technologies and therapeutic solutions for independence and quality of life. Our focus is on significant areas of clinical need, such as wound management, cardiovascular diseases, and autoimmune diseases.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "likely," "estimated," and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Liberty Biopharma may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Liberty Biopharma. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Liberty Biopharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575
SOURCE: Liberty Biopharma Inc.